Reported Wholesale Price Changes Ahead of Patent Expiration: 89 Blockbuster Drugs With California HCAI SB 17 Filings and $51.58B CMS Spend
Joining 5,355 California Health and Human Services (CalHHS) HCAI Senate Bill 17 Wholesale Acquisition Cost (WAC) filings (28,219 historical NDC rows) with FDA Orange Book patent schedules and CMS drug spending identifies 89 approaching-LOE brand prescriptions ($51.58B in 2024 CMS spend) that reported cumulative two-year wholesale list-price changes exceeding California's 16% statutory reporting threshold.
How California Senate Bill 17 Documents Late-Lifecycle Wholesale List-Price Changes
Under California Health and Safety Code Sections 127677 and 127679 (enacted via Senate Bill 17), prescription drug manufacturers must notify and submit quarterly cost-transparency filings to CalHHS HCAI whenever a drug with a Wholesale Acquisition Cost of at least $40 for a course of therapy experiences a cumulative WAC increase exceeding 16% over the current calendar year and prior two calendar years. Across Cliff Ledger's reconciled 2023 to 2026 HCAI panel, 1,345 FDA-approved drugs across 406 consolidated sponsors matched by 11-digit National Drug Code (NDC), with 849 distinct therapies crossing the >16% statutory WAC reporting threshold.
Standard economic textbooks predict that manufacturers facing approaching generic competition should moderate list prices to defend market share. Empirical pharmaceutical list-price schedules frequently move in the opposite direction: during the final 24 to 48 months before core Loss of Exclusivity, sponsors often file January Wholesale Acquisition Cost adjustments across commercial formularies prior to AB-rated generic entry. Even after Medicaid Best Price and Medicare Part D inflation-rebate adjustments under the Inflation Reduction Act, higher undiscounted WAC baselines can affect coinsurance calculations for uninsured patients and commercial high-deductible health plan members whose point-of-sale shares reference list prices prior to PBM rebate reconciliation.
Top Twelve Near-LOE Blockbusters With California SB 17 Wholesale Price Filings
Table 1 ranks the twelve largest near-LOE prescription franchises in summary.top_sb17_pre_cliff_hikes by 2024 CMS Part D plus Medicaid spending. Together, leading cardiovascular, oncology, and immunology therapies such as Eliquis (+19.1% max 2-year cumulative WAC change across 12 NDC filings), Entresto (+22.62% across 12 NDC filings), and Xtandi (+16.75% reaching $14,332 WAC) illustrate reported pre-LOE wholesale price trajectories.
| Brand (Generic Ingredient) | Consolidated Sponsor | Core Substance LOE | SB 17 Filings | Max 2-Yr WAC Change | Latest Filed WAC | 2024 CMS Spend |
|---|---|---|---|---|---|---|
| Eliquis Apixaban | Bristol Myers Squibb | 2027-05-21 | 12 | +19.10% | $991 | $22.07B |
| Entresto Sacubitril/Valsartan | Novartis | 2027-11-27 | 12 | +22.62% | $2,064 | $4.64B |
| Xtandi Enzalutamide | Astellas Pharma | 2027-08-13 | 3 | +16.75% | $14,332 | $3.55B |
| Jakafi Ruxolitinib Phosphate | Incyte | 2028-12-12 | 15 | +19.97% | $17,465 | $2.24B |
| Ofev Nintedanib Esylate | Boehringer Ingelheim | 2026-04-01 | 6 | +19.19% | $12,997 | $2.20B |
| Xifaxan Rifaximin | Bausch Health | 2027-09-02 | 13 | +27.68% | $4,034 | $1.57B |
| Abilify Maintena Aripiprazole | Otsuka Pharmaceutical | 2027-03-02 | 8 | +19.54% | $2,820 | $1.45B |
| Opsumit Macitentan | Johnson & Johnson | 2026-06-05 | 4 | +19.75% | $12,635 | $1.45B |
| Otezla Apremilast | Amgen | 2028-08-16 | 14 | +28.09% | $5,590 | $1.39B |
| Rexulti Brexpiprazole | Otsuka Pharmaceutical | 2029-06-23 | 12 | +21.82% | $1,472 | $1.34B |
| Promacta Eltrombopag Olamine | Novartis | 2026-01-13 | 21 | +28.48% | $21,245 | $902.7M |
| Tyvaso Dpi Treprostinil | United Therapeutics | 2028-12-15 | 5 | +16.53% | $24,362 | $812.0M |
Five-Year National & California Public Drug Spending Trajectory (2020 to 2024)
To contextualize how reported wholesale list-price changes interact with prescription volume growth, Table 2 reports deduplicated national CMS Part D plus Medicaid spending alongside California-headquartered biopharma sponsor revenue from 2020 through 2024 (summary.trends_national and summary.trends_california), paired with 132 therapies exhibiting >=10% compound annual unit-reimbursement growth (CAGR).
| Calendar Year | US Part D Spend | US Medicaid Spend | Combined Clean US Spend | Total US Claims | CA Biopharma Sponsor Spend |
|---|---|---|---|---|---|
| 2020 | $194.09B | $76.42B | $270.52B | 2.13B | $23.16B |
| 2021 | $213.51B | $87.72B | $301.23B | 2.20B | $25.88B |
| 2022 | $239.78B | $100.23B | $340.01B | 2.29B | $29.49B |
| 2023 | $275.81B | $112.31B | $388.12B | 2.40B | $33.85B |
| 2024 | $288.67B | $111.28B | $399.94B | 2.46B | $37.09B |
Statutory Non-Public Narrative Redactions & Payer Audit Takeaways
Auditing the qualitative justification fields inside CalHHS HCAI SB 17 disclosures reveals a consistent regulatory pattern: in a majority of blockbuster filings, manufacturers cite statutory trade-secret exemptions ("Change/improvement withheld as non-public under SB 17; pricing factors withheld as non-public") rather than itemizing new clinical-trial endpoints or manufacturing cost changes. State prescription-drug affordability boards (PDABs), ERISA self-insured employers, and PBM contract auditors can use Cliff Ledger's NDC-to-NDA crosswalk to review every formulary tier-2 or tier-3 brand combining:
- Reported 2-Year SB 17 WAC Change > 16% without newly approved clinical indication exclusivities;
- Core Orange Book Substance LOE Within 36 Months, signaling upcoming generic substitution evaluation windows; and
- Divergent WAC vs. CMS Unit-Reimbursement Growth, comparing list-price changes against public program reimbursement trends subject to statutory CPI-U inflation caps.
Why Pre-LOE Wholesale Price Adjustments Persist Alongside Federal Inflation Rebates
A common assumption among benefits consultants is that the Inflation Reduction Act's Medicare Part D inflation rebates and the American Rescue Plan's removal of the 100%-of-AMP Medicaid rebate cap eliminated manufacturer incentives to adjust Wholesale Acquisition Cost above general inflation. In practice, three commercial contract mechanics explain continued >16% two-year WAC filings across the 89 observed blockbusters:
- Commercial Rebate-Guarantee Mechanics: Pharmacy Benefit Managers frequently structure employer and commercial health-plan contracts around percentage-off-WAC rebate guarantees. Higher list prices on mature tier-2 brands expand nominal rebate pools used to satisfy aggregate rebate guarantees across commercial formularies.
- 340B Ceiling-Price & Deductible Coinsurance Dynamics: While 340B covered entities purchase at statutory ceiling prices once inflation adjustments apply, commercial patients in deductible phases may still encounter coinsurance calculated off gross point-of-sale WAC prior to retrospective rebate pass-through.
- Authorized Generic Reference Benchmarks: Entering the final patent-expiration window at a higher WAC establishes a higher list-price reference point for both branded authorized generics and initial 180-day Paragraph IV generic entrants prior to multi-source generic competition.
Related Cliff Ledger Empirical Studies
- The 2026 to 2030 Pharmaceutical Patent Cliff: Reconciled FDA Orange Book LOE Windows and Medicare Part D plus Medicaid Exposure
- Specialty Drug Launch Pricing Above the Medicare Part D Threshold: California HCAI SB 17 New Drug Introduction Analysis
- Orphan and Biologic Exclusivity Stacking: Why High-Spend Drugs Delay Generic and Biosimilar Entry Past Primary Patent Expiration
- Open Interactive Drug & Sponsor Explorer
- Open 3D Patent-Cliff Horizon Stage